Veranex’s Health Economic Model Demonstrates the Potential Cost-Savings from the French Payer Perspective of Using the EXENT® GAM Assay* for Monitoring Patients with Multiple Myeloma
The investigational model considered the use of the EXENT® GAM Assay from the Binding Site, part of Thermo Fisher Scientific. This is a mass spectrometry method that may replace current immunofixation testing and may inform the timing of bone...
Read More
